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The choice of initial insulin is often dictated by subjective criteria: the “severity” of diabetes, the ability of the
person with diabetes to self inject, at specific times of the day, and the physician’s personal experience. No
objective criteria have been evolved by any expert body so far to help guide clinicians make an appropriate,
and accurate, choice of initiating insulin. Neither have large studies been able to shed light on the preferred
type of insulin regime for a particular individual.
This communication suggests various objective parameters which may be used to inform this decision.
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The appropriate choice of an insulin regime for initi-
ation of therapy has always been a matter of debate.
There is no universal consensus for the optimal method
of starting insulin therapy in patients with type 2 dia-
betes (T2DM) who do not respond to oral anti-diabetic
drugs (OADs). While the American Diabetes Association
(ADA) and European Association for study of Diabetes
(EASD) suggest basal insulin as an initial preferred
strategy [1], the International Diabetes Federation (IDF)
recommends both premixed and basal insulin [2]. Many
national guidelines, on the other hand, support the use
of premixed insulin as a preferred choice for initiation of
therapy [3]. Intensive insulin therapy, too, is indicated as
initial line of management in a select group of patients [1].Postprandial glycemia
Much discussion about the relative merits and demerits
of these approaches revolves around the relevance of
postprandial hyperglycemia. The importance of this entity
in diabetes is beyond doubt. It is proven to be associated,
independently, with risk of micro vascular complication,
macro vascular complications, and mortality. These effects
are mediated by a range of adverse biochemical and cellular
effect, including oxidative stress, dyslipidemia, insulin re-
sistance, altered blood coagulation, endothelial dysfunction,
and increased intima media thickness [4]. The IDF, there-
fore, clearly recommends that treatment strategies which* Correspondence: brideknl@gmail.com
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unless otherwise stated.lower postprandial glycemia must be implemented in those
with postprandial hyperglycemia [5].
This is especially important for Asian populations,
which experience a greater contribution from postpran-
dial hyperglycemia to overall HbA1c [6]. These cohorts
are at risk of greater cardiovascular and all-cause mortal-
ity risk with high postprandial glucose values than with
high fasting glucose levels [7-9]. Much of the discussion
about the appropriateness of basal insulin, therefore,
takes on ethnic tones [10,11]. This is unfortunate, as
both basal and premixed insulin have a definite role to
play in the management of diabetes, in all ethnic groups.Subjectivity vs. objectivity
The choice of initial insulin is often dictated by subject-
ive criteria: the “severity” of diabetes, the ability of the
person with diabetes to self inject, at specific times of
the day, and the physician’s personal experience. No ob-
jective criteria have been evolved by any expert body so
far to help guide clinicians make an appropriate, and ac-
curate, choice of initiating insulin. Neither have large
studies been able to shed light on the preferred type of
insulin regime for a particular individual [4-7,12].
This communication suggests various objective param-
eters which may be used to inform this decision. Shared
decision-making, involving patient and physician, is al-
ways welcome. These objective criteria, based upon sim-
ple physiologic principles, will help characterize the
“hyperglycemia personality”, for both. This is important
for health care professionals, who confront a wide
spectrum of diabetes in clinical practice includingtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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prandial hyperglycemia, and overall hyperglycemia. It is
also relevant for patients, who would like to understand
the rationale behind particular regime.
It must be noted that many of the suggestions listed
below are empirical or experience-based, and still need
to be supported by evidence. However, they all conform
to the school of science known as ‘logical empiricism’.
They are built upon sound logic, and supported by
extensive observation. All these suggestions are easy to
follow at primary care level, and may help improve the
quality of care of people with diabetes. Choice of insulin
therapy is dictated by three parameters: efficacy, safety,
and tolerability. This review aims to help the physician
choose an appropriate insulin regimen, which maintains
safety and tolerability, without compromising efficacy.Short term glycemic indices
Parameter 1: fasting plasma glucose
Fasting plasma glucose (FPG) is a function of hepatic glu-
cose output, and is a prime target for effective anti-diabetes
therapy [1]. Basal insulin is more effective than prandial in-
sulin at controlling fasting glycemia [12]. This observation
is concordant with the basic pharmacology of basal insulin.
Fasting plasma glucose levels, therefore, can be consid-
ered as an objective marker to guide the choice of
insulin preparation. High FPG levels should prompt a
basal insulin prescription, while relatively normal FPG
levels in the setting of uncontrolled HbA1c may encourage
a consideration of alternative regimes.
The drawback with using FPG as a single deciding factor,
however, is that it does not assess the relative contribution
of postprandial hyperglycemia. This value alone does not
help one decide whether to choose a basal or a basal-bolus
regime for management of diabetes. Hence, while it should
be one of the factors used to inform insulin decision mak-
ing, it cannot be the sole marker for this purpose.Table 1 Aid for Insulin Decision (AID)-1
Postprandial glucose excursion
(mg%)
Choice 1 Choice 2








<40 mg% Basal insulin Premixed insulin
(30:70)
The value 74 mg% is taken by calculating PPGE for the diagnostic cut offs for
diabetes (200 mg% and 126 mg%).
The value 40 mg% is taken by calculating PPGE for the diagnostic cut offs for
prediabetic (impaired glucose tolerance 140 mg%, and impaired fasting
glucose 100 mg%).Parameter 2: postprandial glucose
Post prandial glucose (PPG) values represent the pran-
dial component of hyperglycemia. Regular self monitor-
ing of glucose allows one to assess PPG at various times
of the day. The IDF recommends measurement of PPG
1–2 hours after a meal, using self monitoring of blood
glucose (SMBG) [5].
High PPG values imply the need for a rapid acting
insulin, either as part of a premixed regime, as prandial
regime, or as part of a basal-bolus regime. Relative PPG
peaks after each meal may help decide the timing of injec-
tions as well. For example, once daily premixed insulin may
be administered with the meal that leads to the highest
PPG value. Similarly, the timing of the bolus component of
a basal plus regime can be decided accordingly.Postprandial plasma glucose alone, if viewed in isola-
tion, however, suffers the same limitation that FPG does.
As an isolated factor to help insulin decision making,
PPG does not take the contribution of FPG into account.
There should be, for example, a difference in the thera-
peutic strategy for a person with a PPG of 400 mg/dl
and a FPG of 200 mg/dl as compared to another with
PPG of 400 mg/dl and FPG of 300 mg/dl. PPG data is
also limited by lack of uniformity and standardization, as
well as absence of consensus related to timing of assess-
ment, size and quality of meals. Post prandial excursions
may also be relatively less in the background of already
high fasting glucose values. Hence, PPG cannot be used
as a sole factor to drive choice of insulin therapy.Parameter 3: post challenge/post load plasma glucose
The post-challenge or post-load plasma glucose is
taken as a surrogate marker for prandial hypergly-
cemia. These values are an improvement upon post-
prandial glucose values, as they are relatively more
standardized and reproducible. However the concept
of doing post-challenge plasma glucose values in per-
sons with known diabetes is open to criticism: an arti-
ficially induced, invasive, time-consuming procedure
which puts the person at risk of (albeit, temporary)
hyperglycemia does not make good clinical sense.
Mixed meal tolerance tests have been devised to over-
come the issue of an artificial load, but these too, are not
appropriate for routine clinical practice [13]. The use of
post challenge or post load glucose levels to inform the
choice of insulin therapy, therefore, cannot be supported.Parameter 4: postprandial glucose excursion
A simple objective way to measure the relative contribu-
tion of postprandial glucose excursion (PPGE) [14]. Sub-
tracting FPG from PPG provides information about the
need for rapid acting insulin (again, as premixed, as
prandial, or as basal- bolus). Table 1 provides an empir-
ical clinical decision aid to decide insulin regimes based
upon a combination of FPG, PPG and PPGE.
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value of FPG into account. Hence, using PPGE as the only
criteria for therapeutic choice may underestimate the need
for basal insulin. PPGE, therefore, through a simple deci-
sion making aid, must be supplemented by other objective
parameters in order to achieve optimal usefulness.Parameter 5: prandial: fasting index - postprandial glucose
excursion, as a function of fasting plasma glucose
We have discussed the limitation of using FPG, PPG and
PPGE as sole drivers for decision making. Combining
the three objective parameters into a prandial: fasting
index (PFI) obviates some of the concerns discussed
above. We therefore propose the following index:Prandial: fasting index (PFI) = (PPG-FPG) /FPGThe PFI utilizes PPGE (PPG-FPG) as a marker of pran-
dial hyperglycemia, and FPG as a representative of fasting
hyperglycemia. A high ratio implies a higher prandial com-
ponent, which will require premixed or rapid acting insulin
for addressal. A low ratio suggests a greater contribution of
the fasting component of hyperglycemia, and supports the
use of basal insulin.
While the use of this ratio as an aid in insulin decision
making has not been analyzed in a research setting so far,
Table 2 suggests some arbitrary cut offs to determine
choice of insulin regimes. The PFI is limited by the fact that
it does not convey the ‘severity’ of hyperglycemia. For ex-
ample, values of FPG 200 mg/dl, PPG 300 mg/dl give a PFI
of 300-200/200 = 0.5, while results of FPG 100 mg/dl, and
PPG 150 mg/dl also lead to a PFI of 150-100/100 = 0.5.
Thus using PFI alone may not help the treating physician
sense the gravity of a particular clinical situation, and may
lead to inappropriate choices, especially between basal and
basal-bolus regimes.Table 3 Aid for Insulin Decision (AID)-3Long term glycemic indices
Parameter 6: glycated hemoglobin (HbA1c)
The limitation of PFI, discussed in the preceding section,
can be overcome by using HbA1c to provide an accurate
idea of the severity of diabetes. As a single parameter, how-
ever, HbA1c is unable to convey the relative contributions
of fasting and postprandial hyperglycemia. There is robustTable 2 Aid for Insulin Decision (AID)-2
PFI = (PPG-FPG)/FPG Choice 1 Choice 2
>0.6 Rapid acting insulin Premixed insulin (50:50)
0.4-0.6 Premixed insulin (30:70) Premixed insulin (50:50)
<0.4 Basal insulin Premixed insulin (30:70)
The value 0.6 is taken by calculating PFI for the diagnostic cut offs of diabetes
(200 mg%, 126 mg%).
The value 0.4 is taken by calculating PFI for the diagnostic cut offs of prediabetes.data to suggest that fasting glycemia contributes to the bulk
of hyperglycemic burden at high HbA1c [15], and post-
prandial glycemia at lower HbA1c levels. This however,
does not mean that patients with high HbA1c should be
managed with basal insulin alone, while those with rela-
tively lower values should receive rapid acting insulin. Em-
pirically, in fact, basal- bolus regimes are chosen to manage
‘very high’ HbA1c levels, while lesser dose regimes are able
to suffice for patients with ‘less high’ HbA1c.
Parameter 7: fasting plasma glucose (FPG): glycated
hemoglobin (HbA1c) ratio
The limitations discussed for objective parameters based
upon overall status of glycemia (HbA1c) and specific
components of glycemia (FPG, PPG) can be overcome if
both are combined in one ratio. This has been studied
by Vahatalo M et al. [16,17]. The ratio FPG (mmol/l):
HbA1c(%) was used to decide the relative contribution
of fasting glycemia. A cut off of 1.3 was taken, based
upon the diagnostic limit for diabetes based upon FPG
(7.8 mmol/l) and HbA1c (6.0%) [17].
The authors, studying type 2 diabetes patients in a ran-
domized controlled trial setting, compared once daily and
twice daily intermediate acting insulin (neutral protamine
Hagedorn or Lente insulin), with or without oral drug [17].
A ratio of ≥ 1.3 (found in 60% subjects), which suggested
fasting hyperglycemia predominance, responded equally to
all four regimes studied. Persons with a low ratio (<1.3),
suggestive of overall hyperglycemia, responded better to
twice daily insulin.
The same authors observed that ‘fasting type’ hypergly-
cemia is associated with greater body mass index, higher
serum triglyceride, hs-CRP and ALT levels at baseline, and
more weight gain after treatment with insulin. The weight
gain was not dependent on type of basal insulin used. These
observations suggest that ‘fasting type’ hyperglycemia is a
presentation of greater insulin resistance. This hypothesis
was corroborated by the fact that this cohort had a signifi-
cantly higher daily insulin requirement (0.77 IU/kg/day) than
those with ‘overall hyperglycemia’ (0.57 IU/kg/day) [16].
While this study has not compared basal-bolus and
premixed regimes, its results can be used to create an
empirical tool for decision making (Table 3). This, too,FPG/HbA1c Rationale Choice 1 Choice 2
≥ 1.3*
(≥20**)















*The value 1.3 is calculated with the diagnostic cut offs of diabetes using FPG
(7.8 mmol/l) and HbA1c (6%).
**The value 20 is calculated with the diagnostic cut offs for diabetes using
FPG (126 mg%) and currently accepted HbA1c (6.3%) levels.





Fasting plasma glucose (FPG):
glycated hemoglobin
(HbA1c) ratio
Formula PPBG-FPG Prandial: fasting index
(PFI) = (PPG-FPG) /FPG
FPG:HbA1c
Need for HbA1c No No Yes
Need for postprandial blood glucose Yes Yes No
Potential for day to day variability High High Low
Ability to decide need for prandial coverage Good Good Relatively less
Ability to decide need for fasting coverage Relatively less Fair Good
Economy Low cost Low cost High cost due to HbA1c
Ability to calculate based on self monitoring of blood glucose Yes Yes No
FPG: Fasting plasma glucose; PPBG: Postprandial blood glucose.
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limiting factor, however, is that it does not indicate the
absolute severity of the hyperglycemia burden, as men-
tioned for the PFI.Parameter 8: anhydroglucitol
1,5-Anhydroglucitol (1,5-AG) is a six-carbon chain mono-
saccharide and the component of normal human blood
serum. It was first discovered in the plant Polygala senega
in 1888. It is closely correlated with glycometabolism. In
2003, US FDA approved it as a short-term marker of gly-
cemic control. Serum 1,5-anhydroglucitol (1,5-AG) drops
as serum glucose rises above the renal threshold for glucose
and has been proposed as a marker for postprandial
hyperglycemia.
In clinical practice, A1C and 1,5-AG may be used se-
quentially, first utilizing the A1C assay to identify patients
who are moderately or well controlled (A1C 6.5–8.0%) and
then using the 1,5-AG assay to determine the extent of
postprandial glucose excursions. If the A1C is above target
and the 1,5-AG is normal, this would mean that postpran-
dial glucose excursions are not high and the therapy target-
ing basal glucose may be more useful. On the other hand, if
the A1C is above target and the 1,5-AG is low, would re-
flect postprandial glucose elevations [18].
So, a low anhydroglucitol value will imply the need for
an insulin regime which includes a prandial component,
ie, rapid acting insulin or premixed insulin, Such a value
may encourage use of a 50:50 biphasic rather than a
30:70 or 25:75 biphasic insulin (with 25 or 30% being
proportion of rapid acting insulin). Anhydroglucitol,
however, is not available for use in routine clinical prac-
tice, and its cost may limit its utility [19].
If anhydroglucitol estimation were to become readily
available, a simple method of assessing relative postpran-
dial contribution to hyperglycemia would be to calculate
the anhydroglucitol: HbA1c ratio. This may be a moreeffective method of deciding insulin therapy as com-
pared to a single value of anhydroglucitol.Conclusion
Choosing an appropriate regime for insulin initiation is
a difficult task. The large variety of options available to
us, with an equally large list of supporting evidences in
published literature, reinforce the fact that there is no
single answer to this clinical challenge. The current sta-
tus of our knowledge leads to confusion amongst health
care providers, many of whom practice a “one approach
fits all” approach, based on their training and experience.
Such an approach is suboptimal, keeping in mind the
wide diversity of diabetes.
There is a need to develop simple, yet accurate, object-
ive tools to aid in decision making. These tools should
be usable at primary care level, where the vast majority
of people with diabetes take treatment. They should em-
power physicians and people with diabetes to take ap-
propriate decision, instead of confusing them further.
This communication has tried to highlight a few such
objective tools. The prandial fasting index (FPI) and the
FPG/ HbA1c ratio are two promising aids to insulin de-
cision making, which must be studied further in research
as well as clinical settings. The merits and demerits of
three easy- to- use indices, using freely available gly-
cemic parameters, are summarized in Table 4.
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